What are Semax and Selank? A Nootropic Peptide Breakdown
Compound Spotlight
Semax and Selank are frequently discussed together, and they share an unusual status: both are registered pharmaceuticals in Russia, prescribed there for years, while remaining almost entirely unstudied in Western clinical literature. That gap — approved in one jurisdiction, essentially unexamined in another — is the most important thing to understand about them.
Quick summary
- Both are short peptides built on the same design trick: a bioactive fragment fused to a Pro-Gly-Pro tail that resists enzymatic degradation.
- Semax derives from ACTH(4–7) but lacks the hormonal activity of ACTH — no corticosteroid release.
- Selank derives from tuftsin, an immunomodulatory peptide fragment.
- Semax is associated with BDNF upregulation; Selank with GABAergic and serotonergic modulation.
- Both are registered medicines in Russia, used for cognitive and anxiety indications respectively.
- The supporting literature is largely Russian-language, older, small-sample, and not replicated to Western standards. Neither is FDA or EMA approved.
The Pro-Gly-Pro design
Both peptides use the same engineering solution, and it is worth understanding because it explains why they exist in this form.
Short peptides are typically degraded within minutes by peptidases in blood and tissue. Both Semax and Selank append a Pro-Gly-Pro tripeptide to the C-terminal end of their active fragment. Proline residues sharply restrict the conformations a peptide backbone can adopt, and most peptidases cannot process bonds adjacent to proline. The tail therefore acts as an enzymatic shield, substantially extending the molecule’s functional lifespan without altering the active portion.
It is an elegant, economical piece of peptide engineering, and it is the common thread linking two otherwise unrelated compounds.
Semax
Semax is a heptapeptide: the ACTH(4–7) fragment (Met-Glu-His-Phe) plus Pro-Gly-Pro.
The critical point is what it does not retain. Adrenocorticotropic hormone stimulates cortisol release from the adrenal cortex. The 4–7 fragment carries the neuromodulatory activity associated with ACTH in the brain without the hormonal signaling of the intact molecule — Semax does not stimulate corticosteroid release. This mirrors the fragment logic seen elsewhere in this catalog: isolate one function of a larger molecule and discard the rest.
The most-cited mechanistic claim is that Semax increases expression of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus. BDNF supports neuronal survival, synaptic plasticity, and learning, and is one of the more credible molecular targets in cognitive research. Effects on the dopaminergic and serotonergic systems and on inflammatory markers have also been described. In Russia, Semax is registered for indications including ischemic stroke, cognitive disorders, and optic nerve conditions.
Selank
Selank is also a heptapeptide, built from tuftsin (Thr-Lys-Pro-Arg) plus the same Pro-Gly-Pro tail. Tuftsin is a fragment of the immunoglobulin IgG heavy chain with known immunomodulatory activity, which gives Selank a dual character — studied both as an anxiolytic and for immune-related effects.
Its anxiolytic mechanism is described as involving GABAergic modulation, with reported effects on GABA-A receptor expression and on serotonin metabolism. The most-repeated claim about Selank is that it produces anxiolytic effects without the sedation, cognitive impairment, tolerance, or withdrawal associated with benzodiazepines. If that holds, it would be pharmacologically significant, since the trade-off between anxiolysis and sedation is a long-standing limitation of GABAergic drugs. Selank is registered in Russia for anxiety disorders.
How to weigh the evidence
Registration as a medicine in Russia is a real regulatory fact and should not be dismissed. It also should not be read as equivalent to FDA or EMA approval. Approval standards, required trial sizes, and publication norms differ meaningfully between systems, and much of the supporting research for both compounds was conducted within the Soviet and post-Soviet scientific system.
The practical consequences are concrete. Much of the literature is Russian-language and difficult for outside researchers to assess. Studies tend to be small. Trial registration and pre-specified endpoints were not standard practice for much of this work. Independent replication outside Russia is limited. And the mechanistic claims — particularly the BDNF findings — rest on a narrower base than the confidence of their repetition suggests.
As with the Epithalon literature, none of this implies the research is wrong. It means the appropriate posture is interested provisional acceptance rather than confidence, and that claims about these compounds should be presented with the evidentiary context attached.
Frequently asked questions
Does Semax raise cortisol, since it comes from ACTH?
No. The 4–7 fragment retains neuromodulatory activity without the hormonal signaling that drives adrenal corticosteroid release. That separation is the point of using a fragment.
What does the Pro-Gly-Pro tail do?
It protects against enzymatic degradation. Proline restricts backbone conformation and blocks most peptidases from cleaving nearby bonds, extending the peptide’s functional lifespan without changing the active fragment.
If they are approved in Russia, why not elsewhere?
They have not been through FDA or EMA review. Doing so would require trials meeting those agencies’ standards, which has not been undertaken. Approval in one jurisdiction does not transfer to others.
How do I know what is actually in the vial?
Every lot we sell has a published Certificate of Analysis from an independent, third-party lab confirming identity and purity. Lot numbers on the vial should match the COA you are referencing.
References
- Ashmarin IP, et al. Semax as a universal drug for therapy and research. Izv Akad Nauk Ser Biol. 1997.
- Dolotov OV, et al. Semax, an analog of ACTH(4–7), regulates expression of BDNF and trkB in the rat hippocampus. J Mol Neurosci. 2006;28(3):271–280.
- Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neurosci Behav Physiol. 2003.
- Zozulya AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank. Zh Nevrol Psikhiatr. 2008.
View the Semax product listing → | View the Selank product listing →
Look up your lot Certificate of Analysis →
For laboratory and research use only. Not for human consumption. Neither compound is approved by the FDA or EMA. This article summarizes published research for informational purposes and is not medical advice, nor a recommendation or protocol for use.
Related research compounds
Arc Peptides supplies these compounds, each third-party tested for purity and identity with a lot-specific Certificate of Analysis:
For laboratory research use only. Not for human consumption.
